Skip to content

US · JUNS · BIOTECHNOLOGY

Jupiter Neurosciences, Inc. (JUNS) intrinsic value and stock valuation

$1.24as of 2026-11-21 · Mkt cap 2.8M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Jupiter Neurosciences, Inc. DCF and intrinsic value

InvestorsCraft values JUNS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from JUNS’s statements →

Jupiter Neurosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Jupiter, FL 33477 jupiterneurosciences.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$20K-55.4% 5y CAGRd
20192025
Net income
-$-8.64M
20192025
Free cash flow
-$-5.41M
20192025
Total equity
-$-1.83M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$20K$0.00$0.00$230K$640K
Operating income-$-8.91M-$-3.09M-$-3.87M-$-3.43M-$-3.91M
Net income-$-8.64M-$-2.44M-$-4.78M-$-4.96M-$-4.38M
EPSd-$-18.78M-$-6.42M-$-10.86M-$-11.27M-$-33.69M
Operating cash flow-$-5.41M-$-3.91M-$-480K-$-1.25M-$-1.74M
Capital expenditure-$0.00$0.00$0.00$0.00-$0.00
Free cash flow-$-5.41M-$-3.91M-$-480K-$-1.25M-$-1.74M
Total assets$5.56M$6.2M$150K$240K$670K
Total debt$5.32M$220K$2.25M$1.9M$650K
Net debt$1.53M-$-3.55M$2.22M$1.83M$320K
Total equity-$-1.83M$4.17M-$-5.8M-$-7.14M-$-5.18M
Cash and short-term investments$3.79M$3.77M$30K$60K$330K
Income statement
20252024202320222021
Revenue$20K$0.00$0.00$230K$640K
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$20K$0.00$0.00$230K$640K
Research and development expenses$2.09M$490K$950K$940K$1.45M
Selling, general and administrative expenses$6.84M$2.6M$2.92M$2.72M$3.1M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$8.93M$3.09M$3.87M$3.67M$4.55M
Cost and expenses$8.93M$3.09M$3.87M$3.67M$4.55M
Interest income$0.00$10K$0.00$0.00$0.00
Interest expense$70K$250K$220K$740K$110K
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Ebitda-$-8.58M-$-2.19M-$-4.56M-$-4.22M-$-4.09M
Operating income-$-8.91M-$-3.09M-$-3.87M-$-3.43M-$-3.91M
Total other income/expenses, net$260K$650K-$-910K-$-1.53M-$-290K
Income before tax-$-8.64M-$-2.44M-$-4.78M-$-4.96M-$-4.2M
Income tax expense$0.00$0.00$0.00$0.00$180K
Net income-$-8.64M-$-2.44M-$-4.78M-$-4.96M-$-4.38M
Weighted average shares outstanding$460K$380K$440K$440K$130K
Weighted average diluted shares outstanding$460K$380K$440K$440K$130K
Balance sheet
20252024202320222021
Cash and short-term investments$3.79M$3.77M$30K$60K$330K
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$160K$0.00$0.00$0.00$0.00
Total current assets$4.82M$4.65M$30K$70K$450K
Property, plant and equipment, net$20K$70K$120K$160K$210K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$740K$1.55M$120K$170K$210K
Total assets$5.56M$6.2M$150K$240K$670K
Accounts payable$130K$280K$190K$190K$260K
Short-term debt$5.32M$200K$2.07M$1.78M$490K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.4M$2.01M$5.77M$7.26M$5.68M
Long-term debt$0.00$20K$180K$120K$160K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$20K$180K$120K$160K
Capital lease obligations$20K$70K$120K$170K$210K
Total liabilities$7.4M$2.03M$5.95M$7.38M$5.85M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-34.67M-$-26.02M-$-23.58M-$-18.8M-$-13.84M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-1.83M$4.17M-$-5.8M-$-7.14M-$-5.18M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$5.32M$220K$2.25M$1.9M$650K
Net debt$1.53M-$-3.55M$2.22M$1.83M$320K
Cash flow statement
20252024202320222021
Net income-$-8.64M-$-2.44M-$-4.78M-$-4.96M-$-4.2M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$2.42M$1.84M$1.2M$820K$1.3M
Change in working capital$110K-$-2.57M$2.35M$1.55M$780K
Accounts receivable-$0.00$0.00$0.00$0.00$130K
Inventory-$-160K$0.00$0.00$0.00$0.00
Accounts payable$240K-$-150K$160K-$-60K-$-160K
Net cash provided by operating activities-$-5.41M-$-3.91M-$-480K-$-1.25M-$-1.74M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$0.00$9.88M$60K$0.00$830K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$5.43M$7.65M$450K$980K$1.86M
Net change in cash$20K$3.74M-$-40K-$-270K$120K
Cash at end of period$3.79M$3.77M$30K$60K$330K
Operating cash flow-$-5.41M-$-3.91M-$-480K-$-1.25M-$-1.74M
Capital expenditure-$0.00$0.00$0.00$0.00-$0.00
Free cash flow-$-5.41M-$-3.91M-$-480K-$-1.25M-$-1.74M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Jupiter Neurosciences, Inc.

        Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.

        CEO
        Christer Rosen
        Employees
        5
        Beta
        1.96

        Explore

        Frequently asked questions

        What is the intrinsic value of Jupiter Neurosciences, Inc. (JUNS)?

        InvestorsCraft does not currently publish an intrinsic value for JUNS. How the IC value is calculated.

        Is JUNS undervalued?

        InvestorsCraft does not publish an undervaluation signal for JUNS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.